Amgen’s Olpasiran Maintains Competitive Profile In Lp(a) Class
AMG 133 For Obesity Is One To Watch In CV Portfolio
The lipoprotein(a)-lowering antisense drug olpasiran reduced the cardiovascular disease risk factor Lp(a) by up to 101.1% relative to placebo. A Phase III trial will begin in December.
You may also be interested in...
The drug is dosed once every four weeks – compared with Mounjaro and Wegovy’s weekly dosing – but the company also signaled it is considering extended dosing intervals.
The pharma is increasing its manufacturing capacity for tirzepatide, mindful of its potential in a second indication of obesity and the supply issues faced by competitor Novo Nordisk.
The UK biotech could have a major gene silencing drug on its hands but will need a big pharma partner to help it realize the candidate’s potential.